Study of real-world treatment before and after surgery for people with HER2-positive breast cancer

Descriptive study on perioperative treatment in patients with HER2-positive breast cancer - HER2-positive breast cancer treatment pattern study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060989

Enrollment

4000

Registered

2026-03-24

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed with breast cancer between 2018-10-01 and 2024-09-30; 2. Age 18 years or older at diagnosis; 3. Clinical stage I-IIIc at diagnosis; 4. HER2 positivity confirmed at any time during treatment; 5. Breast malignant tumor surgery performed by 2024-09-30.

Exclusion criteria

Exclusion criteria: Record of diagnosis of a non-breast cancer before the diagnosis of breast cancer.

Design outcomes

Primary

Measure	Time frame
Number of patients receiving neoadjuvant systemic therapy from the same calendar day 9 months before breast surgery through the date of surgery, and patient background according to receipt of neoadjuvant systemic therapy.	—

Secondary

Measure	Time frame
Interval from diagnosis to neoadjuvant therapy, duration of neoadjuvant therapy, pathological complete response, interval from surgery to postoperative systemic therapy, use and duration of postoperative systemic therapy and radiotherapy, combinations of preoperative and postoperative treatments, and temporal changes in these patterns.	—

Countries

Japan

Contacts

Public ContactMasafumi Okada

Prime Research Institute for Medical RWD, Inc. Data Science Office

masafumi.okada@ntt.com075-752-0330

Outcome results